Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Raju Mohan Purchases 238,248 Shares

Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Raju Mohan purchased 238,248 shares of the business’s stock in a transaction on Friday, November 22nd. The shares were bought at an average cost of $1.83 per share, with a total value of $435,993.84. Following the acquisition, the chief executive officer now directly owns 1,913,276 shares of the company’s stock, valued at $3,501,295.08. This trade represents a 14.22 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Raju Mohan also recently made the following trade(s):

• On Monday, November 25th, Raju Mohan acquired 261,752 shares of Ventyx Biosciences stock. The shares were bought at an average cost of $2.01 per share, for a total transaction of $526,121.52.

Ventyx Biosciences Stock Performance

VTYX opened at $2.06 on Tuesday. The stock has a market capitalization of $145.66 million, a price-to-earnings ratio of -0.87 and a beta of 0.37. The company has a fifty day moving average of $2.19 and a 200 day moving average of $2.64. Ventyx Biosciences, Inc. has a fifty-two week low of $1.67 and a fifty-two week high of $11.48.

Analysts Set New Price Targets

VTYX has been the topic of a number of recent analyst reports. Oppenheimer restated an “outperform” rating and set a $9.00 target price (down previously from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. Wells Fargo & Company decreased their price objective on shares of Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Canaccord Genuity Group dropped their target price on shares of Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a report on Monday, August 12th. Finally, HC Wainwright reissued a “neutral” rating and set a $6.00 price target on shares of Ventyx Biosciences in a report on Monday, November 11th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in VTYX. Acadian Asset Management LLC bought a new position in Ventyx Biosciences during the second quarter valued at approximately $608,000. Deerfield Management Company L.P. Series C raised its holdings in shares of Ventyx Biosciences by 64.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock worth $13,466,000 after acquiring an additional 2,287,570 shares in the last quarter. Cubist Systematic Strategies LLC boosted its position in shares of Ventyx Biosciences by 165.8% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 149,500 shares of the company’s stock valued at $345,000 after acquiring an additional 93,247 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Ventyx Biosciences by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock valued at $30,000 after purchasing an additional 5,310 shares in the last quarter. Finally, Squarepoint Ops LLC increased its position in Ventyx Biosciences by 101.3% in the second quarter. Squarepoint Ops LLC now owns 76,539 shares of the company’s stock worth $177,000 after purchasing an additional 38,524 shares during the last quarter. Institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.